Related references
Note: Only part of the references are listed.Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis
John W. Rose et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2017)
CD6 gene polymorphism rs17824933 is associated with multiple sclerosis in Indian population
Mary Anitha D'Cunha et al.
ANNALS OF INDIAN ACADEMY OF NEUROLOGY (2016)
Functional Promoter Polymorphisms of MMP-2 C-735T and MMP-9 C-1562T and Their Synergism with MMP-7 A-181G in Multiple Sclerosis
Zohreh Rahimi et al.
IMMUNOLOGICAL INVESTIGATIONS (2016)
Polymorphism in Leptin and Leptin Receptor Genes May Modify Leptin Levels and Represent Risk Factors for Multiple Sclerosis
Mehrdad Farrokhi et al.
IMMUNOLOGICAL INVESTIGATIONS (2016)
Progress and challenges for treating Type 1 diabetes
Justin W. Garyu et al.
JOURNAL OF AUTOIMMUNITY (2016)
Neuroinflammation, neurodegeneration and regeneration in multiple sclerosis: intercorrelated manifestations of the immune response
Tatiana Koudriavtseva et al.
NEURAL REGENERATION RESEARCH (2016)
Epidemiology of Multiple Sclerosis
Jonathan Howard et al.
NEUROLOGIC CLINICS (2016)
Association Between CD24-P226-C/T Polymorphism and Multiple Sclerosis: A Meta-Analysis
Longyang Jiang et al.
IMMUNOLOGICAL INVESTIGATIONS (2015)
GWAS-identified multiple sclerosis risk loci involved in immune response: Validation in Russians
V. V. Bashinskaya et al.
JOURNAL OF NEUROIMMUNOLOGY (2015)
Multiple sclerosis-a quiet revolution
Richard M. Ransohoff et al.
NATURE REVIEWS NEUROLOGY (2015)
Interleukin 2 receptor α chain gene polymorphisms and risks of multiple sclerosis and neuromyelitis optica in southern Japanese
Gulibahaer Ainiding et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Genetic variants in IL2RA and IL7R affect multiple sclerosis disease risk and progression
Anthony L. Traboulsee et al.
NEUROGENETICS (2014)
IL2RA Allele Increases Risk of Neuromyelitis Optica in Southern Han Chinese
Yongqiang Dai et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2013)
The influence of non-HLA gene polymorphisms and interactions on disease risk in a Western Australian multiple sclerosis cohort
Wei Qiu et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Soluble IL-2Rα (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice
Shane E. Russell et al.
PLOS ONE (2012)
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Owain W. Howell et al.
BRAIN (2011)
Interleukin 2 Receptor α Gene Polymorphism and Risk of Multiple Sclerosis: a Meta-analysis
L-M Wang et al.
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH (2011)
Association of IL2RA polymorphisms with susceptibility to multiple sclerosis is not explained by missense mutations in IL2RA
Marcelo Matiello et al.
MULTIPLE SCLEROSIS JOURNAL (2011)
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy
Simone C. Wuest et al.
NATURE MEDICINE (2011)
Polymorphisms in the IL2, IL2RA and IL2RB genes in multiple sclerosis risk
Maria L. Cavanillas et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2010)
Fine mapping of multiple sclerosis susceptibility genes provides evidence of allelic heterogeneity at the IL2RA locus
Devindri Perera et al.
JOURNAL OF NEUROIMMUNOLOGY (2009)
IL2RA Genetic Heterogeneity in Multiple Sclerosis and Type 1 Diabetes Susceptibility and Soluble Interleukin-2 Receptor Production
Lisa M. Maier et al.
PLOS GENETICS (2009)
Replication of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes in Australians
J. P. Rubio et al.
GENES AND IMMUNITY (2008)
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations
F. Weber et al.
GENES AND IMMUNITY (2008)
The crucial role of IL-2/IL-2RA-mediated immune regulation in the pathogenesis of type 1 diabetes, an evidence coming from genetic and animal model studies
Dimitry A. Chistiakov et al.
IMMUNOLOGY LETTERS (2008)
Risk alleles for multiple sclerosis identified by a genomewide study
David A. Hafler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Daclizumab phase II trial in relapsing and remitting multiple sclerosis - MRI and clinical results
J. W. Rose et al.
NEUROLOGY (2007)
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β
B Bielekova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)